536 Intratumoral INT230–6 shows a favorable safety profile and early signs of efficacy in advanced soft tissue sarcoma with monotherapy and in combination with ipilimumab [Intensity IT-01; BMS#CA184–592]

• Anthony Olszanski,
• Lilian Siu,
• Jacob Thomas,
• Diana Hanna,
• Anthony El-Khoueiry,
• Nilofer Azad,
• Lewis Bender,
• Ian Walters,
• Giles Whalen,
• Matthew Ingham,
• Christian Meyer,
• James Hu,
• Syed Mahmood,
• Albiruni Razak

Affiliations

Anthony Olszanski

4Fox Chase Cancer Center, Philadelphia, PA, USA

Lilian Siu

2Princess Margaret Cancer Centre, Toronto, Canada

Jacob Thomas

11Norris Comprehensive Cancer Center, Los Angeles, CA, USA

Diana Hanna

41Division of Medical Oncology, University of Southern California, Hoag Family Cancer Institute, Newport Beach, California, USA

Anthony El-Khoueiry

1University of Southern California, Los Angeles, CA, USA

Nilofer Azad

3Johns Hopkins, Chevy Chase, MD, USA

Lewis Bender

4Intensity Therapeutics, Westport, CT, USA

Ian Walters

4Intensity Therapeutics, Westport, CT, USA

Giles Whalen

5University of Massachussetts, Worcester, MA, USA

Matthew Ingham

6Columbia University, New York, NY, USA

Christian Meyer

Spinal Cord Injury Center, Balgrist University Hospital, Zurich, Switzerland

James Hu

2Keck School of Medicine of USC, Los Angeles, CA, USA

Syed Mahmood

6Intensity Therapeutics, Inc., Westport, CT, USA

Albiruni Razak

7Princess Margaret Cancer Centre, Toronto, Canada